Avoiding glucocorticoid administration in a neurooncological case

Cancer Biology and Therapy

Volumn 4, Issue 11, 2005, Pages 1186-1189

  Rutz, Hans Peter ^a   Hofer, Silvia ^b   Peghini, Pietro E ^b   Gutteck Amsler, Ursula ^b   Rentsch, Katharina ^b   Meier Abt, Peter J ^b   Meier, Urs R ^c   Bernays, René Ludwig ^b  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Division of Radiation Oncology   (Switzerland)

Author keywords

Blood brain barrier; Celecoxib; Cerebrospinal; Dexamethasone; Glioblastoma; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; GADOLINIUM; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; TEMOZOLOMIDE; TROPISETRON;

ADULT; ARTICLE; BRAIN EDEMA; CANCER GRADING; CANCER RISK; CANCER SURGERY; CASE REPORT; CEREBROSPINAL FLUID; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; MALE; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCRIPTION; RADIATION DOSE; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 31144455667     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.11.2232     Document Type: Article

References (41)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114-23.
2. Buckner JC. Factors influencing survival in high grade gliomas. Semin Oncol 2003; 30:10-4.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross IG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96.
4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
5. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002; 360:1969-70.
6. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM. Glucocorticoid cocreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003; 63:3112-0.
7. Rutz HP, Herr I. Interference of glucocorticoids with apoptosis signaling and host tumor interactions. Cancer Biol Ther 2004; 3:715-8.
8. Rutz HP, Herr I. Glucocorticoid administration in antiemetic therapy: Is it safe? Cancer 2005; 103:2656.
9. Das A, Banik NL, Patel SJ, Ray SK. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl 2 ratio and preventing proteolytic activities. Mol Cancer 2004; 3:36-45.
10. Rutz HP. Hydrodynamic consequences of glycolysis: thermodynamic basis and clinical relevance. Cancer Biol Ther 2004; 3:812-5.
11. Harrigan MR, Tuteja S, Neudeck BL. Indomethacin in the management of elevated intracranial pressure: a review. J Neurotrauma 1997; 14:637-50.
12. Bannwarth B, Netter P, Lapicque F, Pere P, Thomas P, Gaucher A. Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity. Eur J Clin Pharmacol 1990; 38:343-6.
13. Wick W, Kuker W. Brain edema in neurooncology: radiological assessment and management. Onkologie 2004; 27:261-6.
14. Chu K, Jeong SW, Jung KH, Han SY, Lee ST, Kim M, Roh JK. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab 2004; 24:926-33.
15. Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase 2 derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 2004; 64:279-85.
16. Kang KB, Wang TT, Woon CT, Cheah ST, Lim YK, Moore XL, Wong MC. Celecoxib enhances brain tumour cell radiosensitivity leading to massive tumour necrosis. Ann Acad Med Singapore 2004; 33:S19-20.
17. Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyciooxygenase 2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 2005; 63:520-8.
18. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase 2 inhibitors. Cancer Res 2000; 60:1306-11.
19. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31:2-11.
20. Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 2004; 3:1217-24.
21. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase 2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl 2. J Biol Chem 2000; 275:11397-403.
22. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase 2 inhibitor celecoxib augments chemotherapeutic drug induced apoptosis by enhancing activation of caspase 3 and 9 in prostate cancer cells. Int J Cancer 2005; 115:484-92.
23. Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, Greiner JW. Combination of a poxvirus based vaccine with a cyclooxygenase 2 inhibitor (celecoxib) elicits antitumor immunity and long term survival in CEA.Tg/MIN mice. Cancer lies 2004; 64:3668-78.
24. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE, 2nd, Dowell JM, Friedman AH, Friedman HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005; 103:329-38.
25. Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schonthal AH. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 2004; 3:55-62.
26. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, Black PM. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS 398. Cancer Res 2000; 60:4926-31.
27. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase 2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61:4375-81.
28. Castilla EA, Prayson RA, Kanner AA, Rybicki LA, Tubbs RR, Vogelbaum MA, Barnett GH. Cyclooxygenase 2 in oligodendroglial neoplasms. Cancer 2003; 98:1465-72.
29. Buccoliero AM, Caldarella A, Arganini L, Mennonna P, Gallina P, Taddei A, Taddei GL. Cyclooxygenase 2 in oligodendroglioma: possible prognostic significance. Neuropathology 2004; 24:201-7.
30. Kim SK, Lim SY, Wang KC, Kim YY, Chi JG, Choi YL, Shin HJ, Cho BK. Overexpression of cyclooxygenase 2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi drug resistance in vitro. Oncol Rep 2004; 12:403-9.
31. Hara A, Okayasu I. Cyclooxygenase 2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol (Berl) 2004; 108:43-8.
32. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M. Cyclooxygenase 2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94:451-5.
33. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase 2 overexpression is a marker of poor prognosis in stage 1 non small cell lung cancer. Clin Cancer Res 2001; 7:861-7.
34. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M. Elevated cyclooxygenase 2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49:1213-7.
35. Koga T, Shibahara K, Kabashima A, Sumiyoshi Y, Kimura Y, Takahashi I, Kakeji Y, Maehara Y. Overexpression of cyclooxygenase 2 and tumor angiogenesis in human gastric cancer. Hepatogastroenterology 2004; 51:1626-30.
36. Demir MK, Hakan T, Akinci O, Berkman Z. Primary cerebellar glioblastoma multiforme. Diagn Interv Radiol 2005; 11:83-6.
37. Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase 2 inhibitors in humans. Anesthesioiogy 2005; 102:409-15.
38. Brautigam L, Vetter G, Tegeder I, Heinkele G, Geisslinger G. Determination of celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2001; 761:203-12.
39. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 2000; 28:514-21.
40. Nam DH, Park K, Park C, Im YH, Kim MH, Lee S, Hong SC, Shin HJ, Kim JH, Eoh W, McDonnell TJ. Intracranial inhibition of glioma cell growth by cyclooxygenase 2 inhibitor celecoxib. Oncol Rep 2004; 11:263-8.
41. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-80.